A. Vehicle development
Quantification was performed by calculating the ratio of the peak area (counts) of C16 and the IS. Results are expressed as relative differences to the peak ratio at 0 h (%RE, Table A ). A.B. Vehicle development for repeated high-dose PO administration of C16
b. Stability test of the 300 mg/kg preparation of C16 in Medigel Sucralose at room temperature
The 300 mg/kg preparation refers to a cup containing 235.29 mg of C16 and 1.64% DMSO (see Materials and Methods section of main text). Sampling took place for a solvent control cup (containing only 1.64% DMSO), and for the medicated cup at 0.17, 5.33, 55, 102 and 144 h post preparation. Samples of 1 mL were withdrawn with syringe and needle through the lid, and mixed with 1 mL of acetonitrile. The supernatant of the resulting suspension was filtered through a Whatman 0.2 µm PTFE syringe filter and analyzed using HPLC-MS. Peak ratios for stability assessment Peak ratios for C16/IS, relative to the first time point, were calculated for three wavelengths (Table D) . Peak ratios for homogeneity assessment of a 300 mg/kg C16-doped gel
HPLC conditions
The 300 mg/kg preparation refers to a cup containing 235.29 mg of C16 and 1.64% DMSO. After preparation (see 'Materials and Methods' section of main text), the gel was sampled through the lid at five sites (Fig A) . The samples were analyzed according to the method described above for the stability test of C16 in Medigel Sucralose (Table E) . The dosing solution was prepared as a cassette to contain all three test articles in the same solution. IV dosing was fixed at 2 mg/mL of C16 and the two other test articles in neat DMSO as the vehicle, with a dosing volume 0.5 mL/kg (slow injection). PO dosing was set at 10 mg/mL of C16 and the two other test articles in neat DMSO as the vehicle, with a dosing volume of 1 mL/kg.
b. Results
Individual plasma concentrations for C16 are shown in Table F and Table G . All data are expressed as ng/mL of the free drug. Samples that were below the limit of quantitation were not used in the calculation of averages. Plasma 
B.B. Mouse blood PK a. Solution preparation
The dosing solution was prepared as a cassette to contain all three test articles in the same solutions using a vehicle consisting of 20% DMSO/10% (DMSO/Cremophor EL 1:1)/70% Milli-Q water.
b. Data
Individual blood concentrations and pharmacokinetic parameters are shown in Table H through Table J 
C. Stability and metabolism
For details on ADME experiments not included underneath, please consult ref. 
b. Results
The areas and percentages for the parent and metabolites have been calculated using MIM data where parent to parent transitions have been used, and assume that each metabolite has the same point of ionisation and the sensitivity of the metabolite has not been affected by the biotransformation. All remaining peaks in the sample were either in the control sample or not believed to be related to test compound. See Table M through Table P . 
D.B. IP Administration
C16 was administered IP at an initial dose of 10 mg/kg to a group of 5 ICR derived male mice weighing 22±2 g. The animals were then observed for presence of acute toxic symptoms and autonomic effects during the first 30 min and after 1 h, 2 h, 6 h and 24 h (Table S-Table U) . The next dose level was determined based on whether more than 50% animals died within 30 min after dosing. Gross necropsy was performed in all animals without tissue collection. Induction is fast (~2 min) and the righting reflex returns after 35-90 min. IMPORTANT. Solutions should always be vigorously shaken and homogenized before use. Higher concentrated solutions of 2,2,2-tribromoethanol are irritating and should not be used. It is advisable to aliquot the solution and protect the material from heat and light. The product is stable for ~15 days when refrigerated. Degraded solutions become acidic and toxic and should be discarded (test: add one drop of Congo red to 5 mL of the solution: purple coloration indicates the solution should no longer be used).
E.B. Toxicology
An overview of all details and raw data is presented in Table V-Table Z . a Start undoped gels in 0, 100 and 300 mg/kg cohorts; b Start treatment with 0, 100 or 300 mg/kg C16 in medicated gels; c Animals were fasted during night between days 6 and 7. 
E.C. Whole blood C16 levels
The concentration of C16 in the individual hemolyzed mouse blood samples is presented in Table AA and Table BB . 38.1±27.8 BLOQ: below the limit of quantitation (0.5 ng/mL). Samples that were below the limit of quantification were not used in the calculation of averages. 
